Overview

Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the effect of the P-glycoprotein inhibitor ritonavir on the pharmacokinetics (PK) of afatinib depending on the timepoint of ritonavir administration
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Afatinib
Ritonavir